Try our Advanced Search for more refined results

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. September 26, 2019

    'Negotiation Class' In Opioid MDL Is Unlawful, 6th Circ. Told

    A first-of-its-kind "negotiation class" designed to seek nationwide settlements in the multidistrict opioid litigation flouts federal law and improperly entices plaintiffs attorneys to cut deals, a group of cities has told the Sixth Circuit.

  2. September 26, 2019

    Opioid MDL Judge Won't Withdraw Over Bias Charge

    The Ohio federal judge overseeing multidistrict opioid litigation refused Thursday to disqualify himself from the historic case, rejecting assertions from drug distributors that he appears biased against them.

  3. September 25, 2019

    Battle Lines Drawn For Opioid MDL's Bellwether Trial

    Drug manufacturers and distributors on Wednesday previewed their attack plans for the first bellwether trial in multidistrict opioid litigation, pinning blame for an addiction epidemic on corrupt doctors, criminal cartels and even the local government plaintiffs themselves.

  4. September 24, 2019

    Opioid MDL Judge Rejects J&J's Attack On Trial Format

    The Ohio federal judge overseeing multidistrict opioid litigation on Tuesday rejected Johnson & Johnson's bid for a bench trial instead of a jury trial on liability for an epidemic of painkiller addiction, saying "12 heads are better than one."

  5. September 20, 2019

    J&J's Litigation Bravado In Sharp Relief After Epic Opioid Trial

    Johnson & Johnson's decision this year to risk a $17 billion penalty in the nation's first opioid-crisis trial added one of the most dramatic chapters yet to the company's increasingly remarkable willingness to spurn settlements and litigate financially perilous cases all the way.

  6. September 19, 2019

    Jury's Task In Ohio Opioid MDL Trial Divides Drug Cos.

    Drug companies involved in multidistrict opioid litigation voiced divergent views in Ohio federal court Thursday on the jury's role in a looming bellwether trial, a question with significant implications for a potential multibillion-dollar remedy.

  7. September 18, 2019

    Opioid 'Negotiation Class' Justifies DQ Bid, Distributors Say

    Drug distributors and pharmacies continued to press their surprise effort to disqualify the judge overseeing the opioid multidistrict litigation, saying his recent approval of a novel negotiation class merits their last-minute play.

  8. September 16, 2019

    4 Key Takeaways As Opioid MDL Distributors Seek Judge's DQ

    An out-of-the-blue crusade by drug distributors and pharmacies to disqualify the judge supervising multidistrict opioid litigation has little chance of succeeding, but it could lay the foundation for future challenges to the judge's sweeping rejection of legal defenses, experts say. Here, Law360 explores four key takeaways about the motion's impetus and likely fate.

  9. September 16, 2019

    Opioid MDL Cos. Accused Of 'Inventing' Comments By Judge

    Attorneys for local governments on Monday accused drug distributors and pharmacies of "inventing" statements by U.S. District Judge Dan Aaron Polster in order to make him appear biased, urging the court to reject the companies' disqualification bid.

  10. September 14, 2019

    Opioid MDL Judge Deserves DQ For Bias, Distributors Say

    Drug distributors and pharmacies on Saturday launched a bold attack on the Ohio federal judge supervising multidistrict opioid litigation, accusing him of appearing deeply biased against them and deserving of disqualification.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!